Effect of ciprofloxacin on the pharmacokinetics of ropivacaine

European Journal of Clinical Pharmacology

Volumn 58, Issue 10, 2003, Pages 653-657

  Jokinen, Mika J ^a,b   Olkkola, Klaus T ^a   Ahonen, Jouni ^a   Neuvonen, Pertti J ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Ciprofloxacin; Drug interaction; Ropivacaine

Indexed keywords

2',6' PIPERCOLOXYLIDIDE; 3 HYDROXYROPIVACAINE; CIPROFLOXACIN; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; DRUG METABOLITE; ROPIVACAINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

EID: 0037299386     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0540-8     Document Type: Article

References (25)

1. McClure JH (1996) Ropivacaine. Br J Anaesth 76:300-307
2. Lee A, Fagan D, Lamont M, Tucker GT (1989) Disposition kinetics of ropivacaine in humans. Anesth Analg 69:736-738
3. Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, Widman M (1996) Metabolism and excretion of ropivacaine in humans. Drug Metab Dispos 24:962-968
4. Oda Y, Furuichi K, Tanaka K, Hiroi T, Imaoka S, Asada A, Fujimori M, Funae Y (1995) Metabolism of the a local anesthetic, ropivacaine, by human hepatic cytochrome P450. Anesthesiology 82:214-220
5. Ekström G, Gunnarsson U-B (1996) Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. Drug Metab Dispos 24:955-961
6. Arlander E, Ekström G, Alm C, Carrillo JA, Bielenstein M, Böttiger Y, Bertilsson L, Gustafsson LL (1998) Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther 64:484-491
7. Jokinen M J, Ahonen J, Neuvonen P J, Olkkola K T (2000) The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine. Anesth Analg 91:1207-1212
8. Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT (2001) Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine. Pharmacol Toxicol 88:187-191
9. Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ (2001) Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. Clin Pharmacol Ther 70:344-350
10. Davis R, Markham A, Balfour JA (1996) Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 51:1019-1074
11. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258
12. Wijnands WJA, Vree TB, van Herwaarden CLA (1986) The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 22:677-683
13. Batty KT, Davis TM, Ilett KF, Dusci LJ, Langton SR (1995) The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 39:305-311
14. Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM (1988) 4-Quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol 35:651-656
15. Raaska K, Neuvonen PJ (2000) Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 56:585-589
16. Arvidsson T, Bruce HF, Halldin MM (1995) Lack of metabolic racemisation of ropivacaine, determined by liquid chromatography using a chiral AGP column. Chirality 7:272-277
17. Kamberi M, Tsutsumi K, Kotegawa T, Nakamura K, Nakano S (1998) Determination of ciprofloxacin in plasma and urine by HPLC with ultraviolet detection. Clin Chem 44:1251-1255
18. Lee A, Fagan D, Lamont M, Tucker GT (1989) Disposition kinetics of ropivacaine in humans. Anesth Analg 69:736-738
19. Rowland M, Tozer T (1995) Clinical pharmacokinetics, concepts and applications. 3rd edn. Williams and Wilkins, Baltimore, p 138
20. Falany CN, Falany JL, Wang J, Hedstrom J, von Euler Chelpin H, Swedmark S (1999) Studies on sulfation of synthesized metabolites from the local anesthetics ropivacaine and lidocaine using human cloned sulfotransferases. Drug Metab Dispos 27:1057-1063
21. Jeppesen U, Gram L F, Vistisen K, Loft S, Poulsen HE, Brøsen K (1996) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51:73-78
22. Emanuelsson B-MK, Zaric D, Nydahl P-A, Axelsson KH (1995) Pharmacokinetics of ropivacaine and bupivacaine during 21 hours of continuous epidural infusion in healthy male volunteers. Anesth Analg 81:1163-1168
23. Erichsen C-J, Sjövall J, Kehlet H, Hedlund C, Arvidsson T (1996) Pharmacokinetics and analgesic effect of ropivacaine during continuous epidural infusion for postoperative pain relief. Anesthesiology 84:834-842
24. Scott DB, Lee A, Fagan D, Bowler GMR, Bloomfield P, Lundh R (1989) Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg 69:563-569
25. Knudsen K, Beckman Suurküla M, Blomberg S, Sjövall J, Edvardsson N (1997) Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth 78:507-514